The Federal Circuit's ruling in Actavis Laboratories FL, Inc. v. United States allows generic pharmaceutical companies to treat legal expenses from defending against Hatch-Waxman patent litigation as ordinary business expenses. This important decision reaffirms the prior ruling by Judge Ryan Holte and obligates the U.S. Government to issue a tax refund of approximately $12 million for 2008-2009. This development highlights significant financial implications for the generic drug sector and the broader context of patent law challenges.
In a recent ruling, the Federal Circuit confirmed that generic pharmaceutical companies can deduct legal expenses associated with Hatch-Waxman patent litigation as ordinary business expenses. This is a victory for the industry.
The decision from the Federal Circuit reinstates the previous ruling by Judge Ryan Holte, favoring Actavis Laboratories in their tax dispute related to patent litigation costs.
As a result of the ruling, the U.S. Government is obligated to refund approximately $12 million in taxes, specifically for the tax years 2008 and 2009.
This case underscores the ongoing legal battles surrounding patent laws and their implications for the pharmaceutical industry, particularly concerning the expenses related to patent defenses.
Collection
[
|
...
]